Skip to main navigation Skip to search Skip to main content

Plasma levels of tumor necrosis factor superfamily molecules are increased in bipolar disorder

  • Izabela G. Barbosa
  • , Gabriela Neves Vaz
  • , Natalia Pessoa Rocha
  • , Rodrigo Machado-Vieira
  • , Marcio Rogerio Diniz Ventura
  • , Rodrigo B. Huguet
  • , Moises E. Bauer
  • , Michael Berk
  • , Antônio L. Teixeira

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Objective: Patients with bipolar disorder (BD) exhibit peripheral low-grade inflammation. The aim of the current study was to investigate the involvement of hitherto unexplored components of the tumor necrosis factor (TNF) superfamily in BD. Methods: Eighty patients with type I BD and 50 healthy controls matched for age and gender were enrolled in this study. All subjects were assessed with the Mini-Plus to evaluate psychiatric comorbidities; the Young Mania Rating Scale and the Hamilton Depression Rating Scale to evaluate manic and depressive symptoms severity, respectively. TNF superfamily molecules (TNF, TNF-related weak inducer of apoptosis [TWEAK], TNF-related apoptosis-inducing ligand [TRAIL], soluble TNF receptor type 1 [sTNFR1], and soluble TNF receptor type 2 [sTNFR2]) levels were measured by ELISA. Results: Patients with BD, regardless of mood state, presented increased plasma levels of sTNFR1 and TWEAK in comparison with controls. Conclusion: These findings corroborate the view that TNF superfamily may play a role in BD pathophysiology.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalClinical Psychopharmacology and Neuroscience
Volume15
Issue number3
DOIs
Publication statusPublished - Aug 2017
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bipolar disorder
  • sTNFR
  • TNF-α
  • TRAIL
  • TWEAK

Cite this